… SARS-CoV-2 and multiple other sarbecoviruses, including SARS-CoV-1, the virus responsible
for the SARS … , was isolated from a patient with SARS-CoV-1. We hypothesized that a …

… A leading theory is that SARS-CoV-2 replicates in an … ), caused substantial reduction in
SARS-CoV-2 replication. The … that target the S1R as early treatment for SARS-CoV-2 infection. …

… pathophysiology of SARS-CoV-2 infection in determining early outpatient treatment of the …
that relate to the patient with early infection treated at home. Therapeutic approaches based …

… , cytokine storm, and thrombosis warrants early interventions to address all components of …
out early treatment can succumb to delayed in-hospital care and death. Prompt early initiation …

… Prolonged shedding of SARS-CoV-2 virus is frequent in HM patients, and this study confirmed
that even in case of early treatment during the Omicron period, 12% were still SARS-CoV-…

… , Doi and colleagues describe successful treatment of patients with early COVID-19 with …
clear SARS-CoV-2 from nasal secretions irrespective if it was started relatively early or later …

… SARS-CoV-2 in patients at high risk who are unlikely to respond to a vaccine. Bebtelovimab
has EUA for early treatment … of tixagevimab–cilgavimab for treatment of early COVID-19 must …

… To determine whether the action of PF-00835231 is consistent with its established role as a
3CL pro inhibitor, and to delineate the timing of early SARS-CoV-2 life cycle stages in A549 +…

… between SARS-CoV-2 … early SARS-CoV-2 infection to severe coronavirus disease 2019
(COVID-19). Understanding the cellular basis of SARS-CoV-2 infection could reveal treatments …

… An exception is remdesivir, which is currently the only drug approved by FDA for the
treatment of moderate-to-severe COVID-19. In the early phases of infection, anti-SARS-CoV-2 …